Omada Health Inc (OMDA) (Q3 2026) Earnings Call Highlights: Record Revenue, Membership
Omada Health Inc (OMDA) reported record revenue and membership growth in Q3 2026. However, new enrollments are expected to decline in Q4 due to seasonality and tough comparisons. GLP-1 market dynamics and rising healthcare costs create uncertainty for 2027. Adjusted EBITDA is expected to moderate due to increased R&D and staffing. The company aims for 20%+ growth in 2027 through expanding covered lives, improving enrollment rates, and increasing engagement.
How this was made
The 30-second read
Why it matters
Guidance points to slower enrollment and moderated EBITDA, suggesting near‑term downside risk but long‑term upside if Flex Care gains traction.
Market read
The earnings call provides fresh guidance that could influence Omada's stock and peers in the digital health space.
What to watch
Potential cost efficiencies from AI‑enabled care teams could mitigate margin pressure.
Background
Omada Health reported Q3 2026 results and provided guidance for Q4 and 2027, highlighting enrollment trends, GLP‑1 product strategy, and cost management.
Ticker impact
The Q3 2026 earnings call disclosed slower Q4 enrollment guidance and moderated EBITDA, indicating near‑term revenue pressure.
likely downside as investors price in slower enrollment and moderated EBITDA.
Guidance is the first public disclosure of slower Q4 enrollments and higher R&D spend, which typically depresses the stock.
Market effects
May weigh on other digital health firms as GLP‑1 coverage uncertainty spreads.
US digital health sector could see modest pullback.
Limited to health‑tech investors; no broad macro effect.
Counterpoint
If GLP‑1 coverage expands, Omada could capture upside from Flex Care adoption.
Key entities
- companyOmada Health Inc
Digital health platform focusing on chronic disease management.
- executiveWei‑Li Shao
President of Omada Health.
- executiveSteve Cook
Chief Financial Officer of Omada Health.
